In AML, MRD was initially applied to the measurement of fusion transcripts: RUNX1-RUNX1T1, CBFb-MYH11 and PML-RARa; and then extended to the detection of residual NPM1 mutated clones [58,59,60,61]. Here, RUNX1 is linked to acute myeloid leukemia.